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Purpose: Cathepsin K is a cysteine protease that has the ca-
pacity to degrade several key matrix components in bone and
cartilage, including type I and II collagens. Balicatib is a novel,
orally bioavailable, speciﬁc cathepsin K inhibitor and potentially
a disease modifying osteoarthritis (OA) drug.
Methods: This randomized, placebo-controlled trial, initially
planned for 12 months, included 152 women and 71 men (mean
age 63) with established knee OA (mean disease duration 10
years) with Kellgren-Lawrence (K-L) grade III at the target knee
and multiple risk factors for disease progression. The contralat-
eral knee was also frequently affected (K-L II 36.8%, K-L III
35.9% and K-L IV 24.7%). The majority of patients had addi-
tionally OA at joints other than the knee (39.9% hand; 61.9%
spine, and 18.8% hip OA). At baseline, median pain on a vi-
sual analogue scale (100mm) was 59 mm (interquartile range
47-73). Patients were randomized to receive either 10 (n=55),
25 (n=55), or 50 mg balicatib (n=58) or a placebo (n=55) daily.
Because of a skin safety signal in a preceding osteoporosis
trial, treatment was terminated early at 6 months, with a 6
month off-treatment follow-up. The primary endpoint was ab-
solute change in most affected medial or lateral compartment
cartilage volume measured by MRI. Bone (serum CTX-I) and car-
tilage markers (urinary CTX-II) of degradation were secondary
endpoints.
Results: There was no statistical signiﬁcant difference of MRI
assessed cartilage volume in the target knee at 6 months (pri-
mary endpoint) between any dose of balicatib and placebo. Six
months after stopping therapy, there was a statistically signiﬁcant
loss of cartilage volume in the two highest doses of balicatib
compared to placebo in the target knee, but not in the contralat-
eral joint. There was a statistical signiﬁcant decrease of CTX-I
and CTX-II in all balicatib groups compared to placebo at 1 and
3 months. After 6 months, the 25 mg dose group showed the
largest decrease compared to placebo with -44.9% (p=0.002)
for CTX-I and -50.3% (p<0.0001) for CTX-II. After treatment
discontinuation a signiﬁcant increase of CTX-I and CTX-II was
seen. At six months after stopping balicatib, CTX-I (+14%, NS)
and CTX-II (+55.6%, p=0.025) remained elevated compared to
placebo for the 50 mg dose group. The rebound increase of
Abstract 230 – Table 1. Radial pQCT vs radiographic knee OA
Radial pQCT K&L P value
(0-1) (2-4) univariate multivariate
mean±sd mean±sd
Radius total area 4% 489.2 (1.1) 487.1 (1.1) 0.76 1.0
Radius total density 4% 326.8 (1.2) 337.6 (1.2) 0.10 0.61
Radius trabecular density 4% 205.9 (1.3) 219.3 (1.3) 0.01 0.09
Radius polar strength strain index 66% 389.6 (1.2) 388.9 (1.3) 0.94 0.89
Radius total area 66% 179.9 (1.2) 181.9 (1.2) 0.51 0.60
Radius cortical density 66% 1113.3 (1.0) 1111.5 (1.0) 0.71 0.70
Radius cortical area 66% 98.6 (1.2) 99.0 (1.2) 0.81 0.67
Radius fracture load x 776.5 (1.2) 777.1 (1.3) 0.98 0.97
Radius fracture load y 847.6 (1.2) 862.8 (1.2) 0.43 0.95
CTX-I after stopping balicatib was more pronounced in women
than in men.
Aside from a higher incidence of skin adverse events (mainly
pruritus; 34.5% in the 25 mg dose group, 23.6% in the placebo
group) and of upper respiratory infections, balicatib was generally
safe and well tolerated at all doses up to 25 mg per day.
The sclerodema/morphea-like skin thickening OP study after 9
months, was not seen under treatment in the OA study, however
1 patient developed a possible case beginning 59 days after stop
of 4 months therapy.
Conclusions: Treatment with balicatib induced a signiﬁcant re-
duction of bone resorption (CTX-I) and type II collagen degra-
dation (CTX-II), but no signiﬁcant effect on cartilage volume as
assessed by MRI could be observed. The increase in bone
and cartilage turnover markers after stopping treatment with the
highest doses of balicatib is investigated further by a continued
follow up of patients. The post-treatment loss of cartilage volume
found with MRI in the target knee could not be conﬁrmed in the
non-target knee. Pruritus and upper respiratory tract infections
were seen more frequently with balicatib than with placebo.
230
IS RADIOGRAPHIC KNEE OSTEOARTHRITIS
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Purpose: Osteoarthritis (OA) has previously been shown to be
associated with an increase in areal bone mineral density as
assessed by DXA scanning. Despite the proven increase in BMD
there is no associated reduction in fracture risk. The aim of
this study is to determine whether knee OA is associated with
changes in volumetric BMD, bone size and strength measured
by pQCT at a site distant from the knee such as the radius.
Methods: We studied men and women from the MRC Hertford-
shire Cohort Study, a population who have been phenotyped for
osteoarthritis and osteoporosis. They have been shown to be
representative of England and Wales. Subjects completed com-
prehensive health questionnaires and underwent detailed anthro-
pometric measurements in addition to weight bearing extended
knee x-rays which were graded for radiographic osteoarthritis
using the modiﬁed Kellgren and Lawrence criteria and for osteo-
phytes. A grade of ≥ 2 was classiﬁed as presence for both OA
and osteophytes. Bone density was also performed at the non-
dominant radius using pQCT (Stratec 4500 instrument); mea-
surements included: radial total density, total area and trabecular
density at the 4% site, radial cortical density, cortical area, total
area and polar strength strain index at the 66% site and radial
fracture load x and y. The associations between OA and pQCT
parameters were analysed using analyses of variance (ANOVA).
